bluebird bio (NASDAQ:BLUE) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of bluebird bio (NASDAQ:BLUE) in a research note issued to investors on Thursday. The firm issued a sell rating on the biotechnology company’s stock.

A number of other equities analysts also recently issued reports on the company. Barclays lowered their price target on bluebird bio from $8.00 to $4.00 and set an “overweight” rating for the company in a report on Thursday, August 15th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $4.00 target price on shares of bluebird bio in a research report on Thursday, August 15th. JPMorgan Chase & Co. downgraded shares of bluebird bio from an “overweight” rating to a “neutral” rating in a research note on Thursday, August 15th. Cantor Fitzgerald reiterated a “neutral” rating on shares of bluebird bio in a research report on Monday, September 16th. Finally, Robert W. Baird reduced their target price on bluebird bio from $7.00 to $6.00 and set an “outperform” rating for the company in a report on Thursday, August 15th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, bluebird bio has an average rating of “Hold” and an average target price of $4.63.

bluebird bio Stock Up 0.9 %

bluebird bio stock opened at $0.49 on Thursday. The firm has a market capitalization of $53.66 million, a P/E ratio of -0.66 and a beta of 0.75. The company has a current ratio of 0.68, a quick ratio of 0.57 and a debt-to-equity ratio of 0.37. bluebird bio has a twelve month low of $0.45 and a twelve month high of $5.53. The stock’s fifty day simple moving average is $0.58 and its 200-day simple moving average is $0.87.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. The company had revenue of $18.57 million during the quarter. bluebird bio had a negative net margin of 567.29% and a negative return on equity of 207.25%. As a group, equities analysts expect that bluebird bio will post -1.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On bluebird bio

Institutional investors and hedge funds have recently bought and sold shares of the stock. Sequoia Financial Advisors LLC raised its holdings in shares of bluebird bio by 48.0% in the first quarter. Sequoia Financial Advisors LLC now owns 40,085 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 13,000 shares during the last quarter. Allegheny Financial Group LTD purchased a new stake in bluebird bio during the 2nd quarter worth about $25,000. Price T Rowe Associates Inc. MD raised its stake in bluebird bio by 113.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company’s stock valued at $71,000 after purchasing an additional 29,113 shares during the last quarter. Bayesian Capital Management LP purchased a new position in bluebird bio in the 1st quarter valued at about $52,000. Finally, American International Group Inc. boosted its stake in shares of bluebird bio by 77.4% during the 1st quarter. American International Group Inc. now owns 94,371 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 41,177 shares during the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.